Loading stock data…
Sana Biotechnology (SANA)
$3.45+0.03 (+0.88%)
Market ClosedLast close Jun 29
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Sana Biotechnology, Inc. in the Healthcare sector is trading at $3.45 with a market capitalization of $788M. Wall Street consensus targets $8.57 (7 analysts), implying a +148.4% move over the next 12 months. The stock is currently 47% below its 52-week high of $6.55, remaining 10.4% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 80 is overbought against a weak tape. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +148.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 80 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$48.61M↑ | -$61.20M↓ | -$43.52M↑ | -$50.36M↑ | -$50.63M |
| Net Income | -$47.21M↑ | -$58.83M↓ | -$42.15M↑ | -$93.80M↓ | -$49.39M |
Peer Comparison
JNJUNHPFE
Fundamentals
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$787.57M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-202.94%
Volume
Today's trading volume
2.49M
Recent News
‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?
Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.View on euronews
Sana Biotech (SANA), Mayo Clinic Partner to Advance Cell Therapy for Type 1 Diabetes
Sana Biotechnology (NASDAQ:SANA) is one of the small cap stocks with the highest upside potential. On April 13, Sana Biotechnology and Mayo Clinic entered into a collaboration to accelerate the development of SC451, an investigational cell replacement therapy for type 1 diabetes. SC451 uses Sana Biotech’s proprietary hypoimmune technology to engineer pancreatic islet cells that […]
Assessing Sana Biotechnology (SANA) Valuation After Mayo Clinic Partnership And Equity Investment
Sana Biotechnology (SANA) is back in focus after Mayo Clinic agreed to collaborate on SC451 for type 1 diabetes and invest up to US$50 million, linking clinical expertise with fresh capital support. See our latest analysis for Sana Biotechnology. The Mayo Clinic collaboration and recent equity raises have arrived alongside a 7.3% 7 day share price return and an 18.3% 30 day share price return, while the 1 year total shareholder return is very large. This suggests that momentum has picked up...
Wedbush Lifts PT on Sana Biotechnology (SANA) to $7 From $6
Sana Biotechnology, Inc. (NASDAQ:SANA) is one of the best stocks under $5 with huge upside potential. Wedbush lifted the price target on Sana Biotechnology, Inc. (NASDAQ:SANA) to $7 from $6 on April 14, reaffirming an Outperform rating on the shares. The firm stated that the company announced a collaboration with the Mayo Clinic to develop […]
Kailera nets $625M in one of biotech’s biggest-ever IPOs
The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to support a portfolio of medicines licensed from China’s Hengrui Pharma.